Literature DB >> 21336285

Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease.

Alexandre Harari1, Virginie Rozot, Felicitas Bellutti Enders, Matthieu Perreau, Jesica Mazza Stalder, Laurent P Nicod, Matthias Cavassini, Thierry Calandra, Catherine Lazor Blanchet, Katia Jaton, Mohamed Faouzi, Cheryl L Day, Willem A Hanekom, Pierre-Alexandre Bart, Giuseppe Pantaleo.   

Abstract

Rapid diagnosis of active Mycobacterium tuberculosis (Mtb) infection remains a clinical and laboratory challenge. We have analyzed the cytokine profile (interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2)) of Mtb-specific T cells by polychromatic flow cytometry. We studied Mtb-specific CD4+ T cell responses in subjects with latent Mtb infection and active tuberculosis disease. The results showed substantial increase in the proportion of single-positive TNF-α Mtb-specific CD4+ T cells in subjects with active disease, and this parameter was the strongest predictor of diagnosis of active disease versus latent infection. We validated the use of this parameter in a cohort of 101 subjects with tuberculosis diagnosis unknown to the investigator. The sensitivity and specificity of the flow cytometry-based assay were 67% and 92%, respectively, the positive predictive value was 80% and the negative predictive value was 92.4%. Therefore, the proportion of single-positive TNF-α Mtb-specific CD4+ T cells is a new tool for the rapid diagnosis of active tuberculosis disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21336285      PMCID: PMC6570988          DOI: 10.1038/nm.2299

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  22 in total

Review 1.  Immunology of tuberculosis.

Authors:  J L Flynn; J Chan
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

Review 2.  Clinical practice. Latent tuberculosis infection.

Authors:  Robert M Jasmer; Payam Nahid; Philip C Hopewell
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

Review 3.  Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.

Authors:  Giuseppe Pantaleo; Richard A Koup
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

4.  Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice.

Authors:  T Meier; H-P Eulenbruch; P Wrighton-Smith; G Enders; T Regnath
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

Review 5.  How can immunology contribute to the control of tuberculosis?

Authors:  S H Kaufmann
Journal:  Nat Rev Immunol       Date:  2001-10       Impact factor: 53.106

6.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

7.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

Authors:  J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

8.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

9.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

10.  An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Authors:  Alexandre Harari; Pierre-Alexandre Bart; Wolfgang Stöhr; Gonzalo Tapia; Miguel Garcia; Emmanuelle Medjitna-Rais; Séverine Burnet; Cristina Cellerai; Otto Erlwein; Tristan Barber; Christiane Moog; Peter Liljestrom; Ralf Wagner; Hans Wolf; Jean-Pierre Kraehenbuhl; Mariano Esteban; Jonathan Heeney; Marie-Joelle Frachette; James Tartaglia; Sheena McCormack; Abdel Babiker; Jonathan Weber; Giuseppe Pantaleo
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

View more
  174 in total

1.  Diagnostic Usefulness of Cytokine and Chemokine Levels in the Cerebrospinal Fluid of Patients with Suspected Tuberculous Meningitis.

Authors:  Ji-Soo Kwon; Joung Ha Park; Ji Yeun Kim; Hye Hee Cha; Min-Jae Kim; Yong Pil Chong; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Yong Seo Koo; Sang-Beom Jeon; Sang-Ahm Lee; Sung-Han Kim
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

2.  Differentiation of antigen-specific T cells with limited functional capacity during Mycobacterium tuberculosis infection.

Authors:  Yun Hee Jeong; Bo-Young Jeon; Sun-Hwa Gu; Sang-Nae Cho; Sung Jae Shin; Jun Chang; Sang-Jun Ha
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

Review 3.  Clinical immunology and multiplex biomarkers of human tuberculosis.

Authors:  Gerhard Walzl; Mariëlle C Haks; Simone A Joosten; Léanie Kleynhans; Katharina Ronacher; Tom H M Ottenhoff
Journal:  Cold Spring Harb Perspect Med       Date:  2014-12-04       Impact factor: 6.915

4.  Role of QuantiFERON-TB Gold antigen-specific IL-1β in diagnosis of active tuberculosis.

Authors:  Maddineni Prabhavathi; Basirudeen Syed Ahamed Kabeer; Anbarasu Deenadayalan; Alamelu Raja
Journal:  Med Microbiol Immunol       Date:  2014-12-11       Impact factor: 3.402

Review 5.  Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus.

Authors:  Samuel M Behar; Stephen M Carpenter; Matthew G Booty; Daniel L Barber; Pushpa Jayaraman
Journal:  Semin Immunol       Date:  2014-10-11       Impact factor: 11.130

6.  Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response.

Authors:  Toidi Adekambi; Chris C Ibegbu; Stephanie Cagle; Ameeta S Kalokhe; Yun F Wang; Yijuan Hu; Cheryl L Day; Susan M Ray; Jyothi Rengarajan
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

7.  Activation Profile of Mycobacterium tuberculosis-Specific CD4(+) T Cells Reflects Disease Activity Irrespective of HIV Status.

Authors:  Katalin A Wilkinson; Tolu Oni; Hannah P Gideon; Rene Goliath; Robert J Wilkinson; Catherine Riou
Journal:  Am J Respir Crit Care Med       Date:  2016-06-01       Impact factor: 21.405

8.  Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.

Authors:  A Singh; A Mohan; A B Dey; D K Mitra
Journal:  Clin Exp Immunol       Date:  2016-11-24       Impact factor: 4.330

9.  Multi-functional flow cytometry analysis of CD4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with tumour necrosis factor (TNF) antagonists.

Authors:  I Sauzullo; R Scrivo; F Mengoni; A Ermocida; M Coppola; G Valesini; V Vullo; C M Mastroianni
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

10.  Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus.

Authors:  Nathella Pavan Kumar; Rathinam Sridhar; Vaithilingam V Banurekha; Mohideen S Jawahar; Thomas B Nutman; Subash Babu
Journal:  J Infect Dis       Date:  2013-05-28       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.